Exploring utilities and outcomes with infliximab therapy.
Inadomi
John M
JM
Terdiman
Jonathan
J
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003424:Crohn Disease / Q000188:drug therapy* / Q000401:mortality; D003661:Decision Support Techniques; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D000069285:Infliximab; D008223:Lymphoma / Q000209:etiology / Q000401:mortality; D011788:Quality of Life; D019057:Quality-Adjusted Life Years; D012074:Remission Induction; D018570:Risk Assessment; D018805:Sepsis / Q000209:etiology / Q000401:mortality
D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D000069285:Infliximab